Scivanta Medical Corporation reported earnings results for the third quarter ended July 31, 2009. For the quarter, the company's net loss was $341,718, up $449,243 for the same quarter the previous year.

Scivanta Medical Corporation reported earnings results for the second quarter ended April 30, 2009. For the quarter, the company reported net loss of $438,763. In contrast, the company posted a net loss of $388,036 for the same quarter in the previous year.

Scivanta Medical Corp. said in a SEC 10-Q filing that, “The Company had working capital of $350,587 and cash and cash equivalents on hand of $891,995 as on January 31, 2009. The $293,351 increase in cash on hand from October 31, 2008 was primarily due to the receipt of $512,354 of net proceeds related to the sale of a portion of our unused net operating loss carryovers for the State of New Jersey to a third party through the 2008 NJEDA Technology Business Tax Certificate Transfer Program and the receipt of $211,438 of receivables due from the Foundation and Ethox, offset by our continuing operating expenses. During the past several years, Scivanta has generally sustained recurring losses and negative cash flows from operations. We currently do not generate any revenue from operations. Our operations most recently have been funded through a combination of the sale of our convertible debentures and common stock, proceeds received from the settlement of litigation and the sale of our State of New Jersey tax losses. As of March 13, 2009, our cash position was approximately $664,000. Based on this, without any additional financing, we will be able to continue our administrative operations and a very small amount of our HCMS development activities for approximately seven to nine months from the filing date of this report. As a result of our current liquidity position, our auditors have expressed substantial doubt that we can continue as a going concern. Our financial statements do not include any adjustments related to this uncertainty. We currently do not have any lending relationships with commercial banks and do not anticipate establishing such relationships in the foreseeable future due to our limited operations and assets. We believe that our focus should be on obtaining additional capital through the private placement of our securities. We are aggressively pursuing potential equity and or debt investors and have engaged several placement agents to assist us in this initiative. In addition, we are reducing operating expenses. While we are aggressively pursuing the opportunities and actions described above, there can be no assurance that we will be successful in our efforts. If we are unable to secure additional capital, we will explore other strategic alternatives, including, but not limited to, the sale of the company. Any additional equity financing may result in substantial dilution to our stockholders.”